中国继续医学教育
中國繼續醫學教育
중국계속의학교육
CHINA CONTINUING MEDICAL EDUCATION
2015年
21期
180-181
,共2页
奈达铂%顺铂%宫颈癌%同步放化疗%疗效
奈達鉑%順鉑%宮頸癌%同步放化療%療效
내체박%순박%궁경암%동보방화료%료효
Nedaplatin%Cisplatin%Cervical cancer%Concurrent chemoradiotherapy%The curative effect
目的:研究奈达铂以及顺铂应用于宫颈癌同步放化疗中发挥的作用。方法选择48例中晚期宫颈癌化疗患者,对照组24例采用奈达铂实施同步放化疗,观察组24例应用顺铂开展同步放化疗。结果两组患者总体治疗有效率差异无统计学意义(P >0.05);观察组血小板减少发生率为34.2%,低于对照组的63.2%(P <0.05);观察组肝肾功能损害发生率高于对照组(P <0.05)。结论针对宫颈癌中晚期患者,选择奈达铂以及顺铂进行同步放化疗均能够取得良好疗效,两种药物所引发的临床不良反应存在一定差异。
目的:研究奈達鉑以及順鉑應用于宮頸癌同步放化療中髮揮的作用。方法選擇48例中晚期宮頸癌化療患者,對照組24例採用奈達鉑實施同步放化療,觀察組24例應用順鉑開展同步放化療。結果兩組患者總體治療有效率差異無統計學意義(P >0.05);觀察組血小闆減少髮生率為34.2%,低于對照組的63.2%(P <0.05);觀察組肝腎功能損害髮生率高于對照組(P <0.05)。結論針對宮頸癌中晚期患者,選擇奈達鉑以及順鉑進行同步放化療均能夠取得良好療效,兩種藥物所引髮的臨床不良反應存在一定差異。
목적:연구내체박이급순박응용우궁경암동보방화료중발휘적작용。방법선택48례중만기궁경암화료환자,대조조24례채용내체박실시동보방화료,관찰조24례응용순박개전동보방화료。결과량조환자총체치료유효솔차이무통계학의의(P >0.05);관찰조혈소판감소발생솔위34.2%,저우대조조적63.2%(P <0.05);관찰조간신공능손해발생솔고우대조조(P <0.05)。결론침대궁경암중만기환자,선택내체박이급순박진행동보방화료균능구취득량호료효,량충약물소인발적림상불량반응존재일정차이。
Objective To study the nedaplatin and cisplatin used in cervical cancer chemoradiation plays the role of the work. Methods 48 patients with locally advanced cervical cancer chemotherapy, the control group 24 cases using nedaplatin chemoradiation, observation group of 24 cases with cisplatin in concurrent chemoradiotherapy. Results Two groups of patients overall treatment efficient differences had no statistical significance (P>0.05). Thrombocytopenia rate was 34.2%,the observation group was obviously less than 63.2% in the control group (P<0.05), The incidence of liver and kidney function damage observation group was obviously higher than that of control group (P<0.05). Conclusion For patients with cervical cancer middle-late, nedaplatin, choose platinum and cisplatin chemoradiation can achieve good curative effect, the two drugs clinical adverse reactions caused by there exist certain differences.